DB00020 Protein chemical formula C 639 H 1006 N 168 O 196 S 8 Protein average weight 144345000 Description Sargramostim is a human recombinant granulocyte macrophage colonystimulating factor GMCSF expressed in yeast It is a glycoprotein that is 127 residues ID: 919321
Download Presentation The PPT/PDF document "Sargramostim Drugbank ID :" is the property of its rightful owner. Permission is granted to download and print the materials on this web site for personal, non-commercial use only, and to display it on your personal computer provided you do not modify the materials and that you retain all copyright notices contained in the materials. By downloading content from our website, you accept the terms of this agreement.
Slide1
Sargramostim
Drugbank
ID :
DB00020
Protein chemical
formula :
C
639
H
1006
N
168
O
196
S
8
Protein
average
weight :
14434.5000
Slide2Description
:
Sargramostim
is a human recombinant granulocyte macrophage colony-stimulating factor (GM-CSF) expressed in yeast. It is a glycoprotein that is 127 residues. Substitution of Leu23 leads to a difference from native protein.
Indication
:
For the treatment of cancer and bone marrow transplant
Pharmacodynamics
:
Sargramostim
is used in the treatment of bone marrow transplant recipients or those exposed to chemotherapy an recovering from
acut
myelogenous
leukemia
,
Leukine
or GM-CSF is a hematopoietic growth factor which stimulates the survival,
clonal
expansion (proliferation) and differentiation of hematopoietic progenitor cells. GM-CSF is also capable of activating mature granulocytes and macrophages. After a bone marrow transplant or chemotherapy, patients have a reduced capacity to produce red and white blood cells. Supplementing them with external sources of GM-CSF helps bring the level of
neutrophils
back to normal so that they can better fight infections.
Slide3Mechanism of action
:
Sargramostim
binds to the Granulocyte-macrophage colony stimulating factor receptor (GM-CSF-R-alpha or CSF2R) which stimulates a JAK2 STAT1/STAT3 signal transduction pathway. This leads to the production of
hemopoietic
cells and
neutrophils
Clearance :
420
mL/min/m2 [Normal people with liquid LEUKINE (IV)
]
431
mL/min/m2 [Normal people with lyophilized LEUKINE (IV)
]
549 mL/min/m2 [Normal people with liquid LEUKINE (SC
)
]
529
mL/min/m2 [Normal people with lyophilized LEUKINE (SC)].
Slide4Targets
:
Granulocyte-macrophage colony-stimulating factor receptor subunit alpha,Interleukin-3 receptor subunit
alpha,Cytokine
receptor common subunit beta,Syndecan-2,Bone marrow
proteoglycan
Affected organisms
:
Humans and other mammals
Slide5Categories
:
Immunosuppressive Agents
Patents
:
Country Patent Number Approved Expires
Canada 1341150 2000
-12-
05 2017
-12-05
Sequence
:
APARSPSPSTQPWEHVNAIQEALRLLNLSRDTAAEMNETVEVISEMFDLQEPTCLQTRLELYKQGLRGSLTKLKGPLTMMASHYKQHCPPTPETSCATQIITFESFKENLKDFLLVIPFDCWEPVQE
Slide6Brands
:
Leucomax
Company :
Novartis
Description :
Leucomax
contains a chemical which stimulates the colonies of white stem cells within the bone marrow causing the level of granulocytes in the blood to rise. Increasing the levels granulocytes in the blood stream reduced the risk and severity of infection. In the same way chemotherapy affects the rapidly dividing white cells it can also affect the platelets. The cells which make platelets are also found within the bone marrow, called "platelet stem cells -
megacaryocytes
".
Leucomax
also stimulates
megacaryocytes
and increases the number of platelets into the blood stream thereby reducing the risk of bleeding. (Granulocyte &
Megacaryocyte
stimulating factor - GM-CSF)
Used for/Prescribed for :
Used for: Reducing severe, life-threatening, or fatal infections after chemotherapy for acute
myelogenous
leukemia
(AML). It is also used to help increase the success of
autologous
bone marrow transplant and to help increase survival in patients who have bone marrow transplant failure.
Form :
solution
Route of administration :
subcutaneous and intravenous Injection
Slide7Dosage :
In case of Intravenous Chemotherapy-induced
neutropenia
in Adult: 250 mcg/m 2 daily for up to 42 days as required, to be given as IV infusion over 4 hr
Side effects :
It is common to have aching bones and joints for 2-3 days starting 1-2 days after the start of the injections. This is usually mild and is caused by the bone marrow working harder to More white cells. Occasionally it is more troublesome and pain killers are required. (Provided you don't have a temperature
paracetamol
is often helpful, it is not strong enough ask your doctor about anti-inflammatory drugs. Remember if you feel unwell check your temperature before you due to take your next tablet).
Slide8General references
:
Granulocyte-macrophage colony-stimulating factor receptor subunit alpha,Interleukin-3 receptor subunit
alpha,Cytokine
receptor common subunit beta,Syndecan-2,Bone marrow
proteoglycan
.
Slide9References
:
http://www.cancernet.co.uk/
leucomax.htm
http://www.igenericdrugs.com/?s=leucomax%20%28novartis%29